Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study

References

• Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer. 2015;112(9):1575–1584.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Middleman E, Luce J, Frei E. Clinical trials with adriamycin. Cancer. 1971;28(4):844–850.
   PubMed Web of Science ®Google Scholar
• Tsai HT, Pfeiffer RM, Warren J, et al. The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56(3):682–687.
   PubMed Web of Science ®Google Scholar
• Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22(10):1864–1871.
   PubMed Web of Science ®Google Scholar
• Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26(19):3159–3165.
   PubMed Web of Science ®Google Scholar
• Juul MB, Jensen PH, Engberg H, et al. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: a Danish population-based cohort study. Eur J Cancer. 2018;99:86–96.
   PubMed Web of Science ®Google Scholar
• Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin’s lymphoma: disease presentation, response to treatment, and survival – A groupe d’Etude des lymphomes de l’Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15(8):2945–2953.
   PubMed Web of Science ®Google Scholar
• Ösby E, Hagberg H, Kvaløy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group Randomized Trial. Blood. 2003;101:3840–3848.
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Rossi G, et al. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leuk Lymphoma. 2012;53(4):581–588.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460–468.
   PubMed Web of Science ®Google Scholar
• Oberic L, Peyrade F, Puyade F, et al. Subcutaneous rituximab-MiniCHOP compared with subcutaneous rituximab-MiniCHOP plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older. J Clin Oncol. 2021;39(11):1203–1213.
   PubMed Web of Science ®Google Scholar
• Wästerlid T, Oren Gradel K, Eloranta S, et al. Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group Study. Br J Haematol. 2021;192(3):551–559.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549.
   PubMed Web of Science ®Google Scholar
• Arboe B, Josefsson P, Jørgensen J, et al. Danish national lymphoma registry. Clin Epidemiol. 2016;8:577–581.
   PubMed Web of Science ®Google Scholar
• Arboe B, El-Galaly TC, Clausen MR, et al. The Danish National Lymphoma Registry: coverage and data quality. PLOS One. 2016;11(6):e0157999.
   PubMed Web of Science ®Google Scholar
• Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(7 Suppl.):30–33.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
   PubMed Web of Science ®Google Scholar
• Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, et al. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46(3):798.
   PubMed Web of Science ®Google Scholar
• Wallach Kildemoes H, Toft Sørensen H, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(7 Suppl.):38–41.
   PubMed Web of Science ®Google Scholar
• Heide-Jørgensen U, Adelborg K, Kahlert J, et al. Sampling strategies for selecting general population comparison cohorts. Clin Epidemiol. 2018;10:1325–1337.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
   Web of Science ®Google Scholar
• Lee SF, Luque-Fernandez MA, Chen YH, et al. Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong. Blood Adv. 2020;4(20):5107–5117.
   PubMed Web of Science ®Google Scholar
• Wästerlid T, Mohammadi M, Smedby KE, et al. Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish Lymphoma Register Study. J Intern Med. 2019;285(4):455–468.
   PubMed Web of Science ®Google Scholar
• Salz T, Zabor EC, Brown PdN, et al. Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors. J Clin Oncol. 2017;35(34):3837–3843.
   PubMed Web of Science ®Google Scholar
• Linschoten M, Kamphuis JAM, van Rhenen A, et al. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematol. 2020;7(4):e295–e308.
   PubMed Web of Science ®Google Scholar
• He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996–1002.
   PubMedGoogle Scholar
• Baech J, Hansen SM, Lund PE, et al. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish Nationwide Cohort Study of 2440 lymphoma patients treated with or without anthracyclines. Br J Haematol. 2018;183(5):717–726.
   PubMed Web of Science ®Google Scholar
• Fornaro A, Olivotto I, Rigacci L, et al. Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience. Eur J Heart Fail. 2018;20(5):898–906.
   PubMed Web of Science ®Google Scholar
• Eyre TA, Martinez-Calle N, Hildyard C, et al. Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age. J Intern Med. 2019;285(6):681–692.
   PubMed Web of Science ®Google Scholar
• Hohaus S, Bartolomei F, Cuccaro A, et al. Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis. Cancers. 2020;12(5):1291.
   Web of Science ®Google Scholar
• Lim SH, Woo S-y, Kim S, et al. Cross-sectional study of patients with diffuse large B-cell lymphoma: assessing the effect of host status, tumor burden, and inflammatory activity on venous thromboembolism. Cancer Res Treat. 2016;48(1):312–321.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Uppal NP, Khorana AA, et al. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006;47(6):1029–1033.
   PubMed Web of Science ®Google Scholar
• Borg IH, Bendtsen MD, Bøgsted M, et al. Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57(12):2771–2776.
   PubMed Web of Science ®Google Scholar
• Caruso V, Di Castelnuovo A, Meschengieser S, et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood. 2010;115(26):5322–5328.
   PubMed Web of Science ®Google Scholar
• Mahajan A, Wun T, Chew H, et al. Lymphoma and venous thromboembolism: influence on mortality. Thromb Res. 2014;133:S23–S28.
   PubMed Web of Science ®Google Scholar
• Park LC, Woo SY, Kim S, et al. Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: results from a prospective cohort study with Asian population. Thromb Res. 2012;130(3):e6–e12.
   PubMed Web of Science ®Google Scholar
• Yokoyama K. Thrombosis in lymphoma patients and in myeloma patients. Keio J Med. 2015;64(3):37–43.
   PubMedGoogle Scholar
• Khorana A, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907.
   PubMed Web of Science ®Google Scholar
• Lund JL, Østgård LS, Prandoni P, et al. Incidence, determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark. Thromb Res. 2015;136(5):917–923.
   PubMed Web of Science ®Google Scholar